Submitters Still Confused On Adverse Event Reporting To ClinicalTrials.gov
This article was originally published in The Gray Sheet
Device and drug firms that submit details about their clinical trials to ClinicalTrials.gov are still having problems reporting adverse events data, Deborah Zarin, the Web site's director, told the FDA Risk Communication Advisory Committee Nov. 12
You may also be interested in...
Manufacturer confusion over ClinicalTrials.gov trial registration and reporting requirements is no excuse for failing to make a good-faith attempt at compliance, FDA and NIH officials say
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.